- Company
- Clinical data on use of Repatha in Koreans revealed
- by Son, Hyung-Min Apr 30, 2024 05:49am
- Amgen's dyslipidemia drug Repatha (evolocumab) has demonstrated LDL-cholesterol reduction in an additional trial conducted on Koreans. Based on the verified results, Amgen Korea emphasized the need for early access to Repatha for high-risk patients whose LDL cholesterol is uncontrolled with statins. Amgen Korea held a press conference at
- Company
- Evolving ADC…pharma companies explore new DAC platform
- by Son, Hyung-Min Apr 30, 2024 05:49am
- New forms of technology utilizing the antibody-drug conjugate (ADC) are global trends. One such form is the degrader-antibody conjugate (DAC), a conjugate with the ADC merged with targeted protein degradation (TPD). According to industry sources on the 27th, Biotech companies, including Orum Therapeutics, Nurix Therapeutics, Prelude Therapeut
- Company
- Patients request Leqembi’s reimb even before approval
- by Eo, Yun-Ho Apr 29, 2024 05:50am
- More specifically, the drug is indicated for ‘slowing progression of mild cognitive impairment (MCI) and mild dementia due to&160;Alzheimer's disease.’ Leqembi has been proven to reduce the rate of disease progression and slow cognitive decline by selectively binding to amyloid beta (Aβ) aggregates, which are a known cause of Alzheime
- Company
- After 9 years, greenlight for 'Ilaris' reimbursement likely
- by Eo, Yun-Ho Apr 29, 2024 05:49am
- In about nine years since its approval in South Korea, the orphan drug 'Ilaris' is heading toward reimbursement listing. Novartis’ continued effort has shined. In February, Ilaris (canakinumab), a drug used to treat periodic fever syndromes (PFS), received a conditional pass decision from the Drug Reimbursement Evaluation Committee (DREC
- Company
- A change in the DPP4 diabetes market worth KRW 600 billion
- by Kim, Jin-Gu Apr 26, 2024 05:48am
- The market for DPRR-4 inhibitor class diabetes treatment, valued at KRW 600 billion annually, is undergoing a significant shift. Following the expiration of substance patents for major original products, generics have been launched, rapidly expanding their prescriptions. At the same time, the growth of original products is experiencing a sl
- Company
- ‘HTL is the best global partner for Korean companies'
- by Lee, Seok-Jun Apr 26, 2024 05:48am
- There is an easy way for domestic pharmaceutical companies wishing to go global: meet a partner that has extensive experience in entering the global market. The companies can speed up their global expansions by receiving the partner's know-how and minimizing trial and error. Time is money. Especially in the rapidly changing pharmaceutical and
- Company
- LG Chem-EuBiologics will locally manufacture vaccines
- by Kim, Jin-Gu Apr 26, 2024 05:47am
- LG Chem is joining hands with EuBiologics to speed up the development of pediatric combination vaccines that are being fully imported. LG Chem announced today that it has signed an agreement with EuBiologics to outsource the production of 'acellular Pertussis (aP)', the main antigen used for its hexavalent combination vaccine 'LR20062.
- Company
- Forxiga prescriptions 'drop' after a 'withdrawal notice'
- by Kim, Jin-Gu Apr 25, 2024 05:50am
- The prescription sales of ‘Forxiga (dapagliflozin),’ an SGLT-2 inhibitor class treatment for diabetes, have declined to 22% over a year. After announcing its withdrawal from the Korean market at the end of last year, the company has distributed only the remaining stocks of Forxiga in South Korea, which may have impacted prescription sales
- Company
- Godex’s sales slow down due to various regulatory measures
- by Chon, Seung-Hyun Apr 25, 2024 05:50am
- Celltrion’s liver drug 'Godex' is experiencing a slump in the prescription market. At one point, its quarterly prescription sales exceeded KRW 20 billion but have been on a downward trend for the past 2 years. The company has been able to pass the health authorities' reimbursement reevaluations, but the drug price cut that followed left a perfo
- Company
- Lipitor’s sales stay strong for good reason
- by Son, Hyung-Min Apr 25, 2024 05:50am
- The dyslipidemia treatment Lipitor has been able to remain the No. 1 selling drug for 20 years, supported by various clinical evidence. Lipitor has proven its efficacy in patients with dyslipidemia not only globally but also domestically. Based on various clinical evidence, major domestic and international societies still recommend statins a
